Medtronic (MDT) EVP Michael Marinaro Sells $1M of Stock

Medtronic plc Executive Vice President Michael Marinaro sold 10,420 shares of the medical device maker on October 15, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the shares were sold at a price of $96.00 each, bringing the total value of the transaction to roughly $1.0 million. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan.

Inside Michael Marinaro's Medtronic Trade

The transaction involved 10,420 shares of common stock, executed at $96.00 per share for a total reported value of $1,000,320.00. Following this pre-planned sale, Marinaro holds remaining shares in the healthcare company. The filing provides a window into executive transactions at the Galway, Ireland-based device manufacturer.

Other Institutional Activity in Medtronic

Other major financial institutions have adjusted their positions in Medtronic recently. Traphagen Investment Advisors acquired a new stake containing 2,361 shares worth about $203,704 on October 14, 2026. Summit Financial Strategies also opened a position on October 14, 2026, buying 2,327 shares valued at roughly $200,797. Patriot Financial Group Insurance Agency grew its holdings by 9,976 shares, ending with 49,893 shares worth about $4,305,290. Massachusetts Financial Services Co. reduced its holdings by 1,564,940 shares, ending with 19,872,600 shares worth about $1,882,928,850 on June 30, 2026. Deutsche Bank AG cut its stake by 552,983 shares, holding 18,449,877 shares valued at about $1,748,125,845 as of June 30, 2026.

Medtronic plc Stock Down 1.0%

Medtronic shares recently traded around $94.46, sitting 1.0% below the event close price of $95.45 recorded on October 15, 2026. The stock trades above both its 50-day moving average of $90.71 and its 200-day moving average of $88.31. Shares sit 11.2% below their 52-week high of $106.33 and 28.9% above their 52-week low of $73.31.

Recent Earnings

For the trailing twelve months, Medtronic generated $37.54 billion in revenue and reported diluted earnings of $4.07 per share. The firm generated a net profit margin of 13.9% and a return on equity of 10.6%. Its next quarterly financial update is scheduled for November 17, 2026.

Dividend

Medtronic pays an annual dividend rate of $2.88 per share, yielding 3.02% based on recent trading levels. The company maintains a dividend payout ratio of 70.0%.

Insider Buying and Selling at Medtronic plc

Executive selling activity has occurred alongside other recent insider moves at Medtronic. Officer Harry Skip Kiil sold 4,189 shares for $336,965 on June 8, 2026. Officer Matthew R. Walter sold 3,102 shares at $83.15 per share for a total value of $257,931 on July 8, 2026. Later, on September 16, 2026, Harry Skip Kiil sold 1,483 shares at $93.65 per share totaling $138,883. Additionally, CEO Geoffrey Martha sold 50,000 shares on October 15, 2026.

Analysts Set New Price Targets

Wall Street analysts continue to update their views on Medtronic shares. Truist Securities reiterated a Hold rating with a $99.00 price target on September 2, 2026. UBS maintained a Buy rating, raising its target to $110.00 on September 3, 2026. TD Cowen reiterated a Buy rating with a $110.00 price target on September 30, 2026. Barclays initiated coverage with an Equal-Weight rating and a $95.00 price target on October 7, 2026. BTIG maintained a Buy rating with a $99.00 target on October 12, 2026. The stock carries a consensus buy recommendation and a mean price target of $104.40 across 25 analyst opinions.

About Medtronic

Medtronic plc designs and manufactures medical technologies, devices, and therapies for healthcare providers and patients worldwide. The company organizes its operations across three primary segments focused on cardiovascular solutions, neuroscience equipment, and medical surgical products. Its systems are deployed globally in hospitals and clinics to treat a wide range of chronic and acute medical conditions.

Bottom Line

Michael Marinaro's planned sale of 10,420 shares provides investors with another data point on executive transactions at Medtronic. Observers will look ahead to the company's next earnings report on November 17, 2026, for additional details on financial performance and segment growth.